- Home
- ADIL vs INBS Comparison
ADIL vs INBS Comparison
Compare ADIL & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- INBS
- Stock Information
- Founded
- ADIL 2010
- INBS 2016
- Country
- ADIL United States
- INBS United States
- Employees
- ADIL N/A
- INBS N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- INBS Medical Specialities
- Sector
- ADIL Health Care
- INBS Health Care
- Exchange
- ADIL Nasdaq
- INBS Nasdaq
- Market Cap
- ADIL 6.5M
- INBS 6.3M
- IPO Year
- ADIL 2018
- INBS N/A
- Fundamental
- Price
- ADIL $1.12
- INBS $1.29
- Analyst Decision
- ADIL Strong Buy
- INBS
- Analyst Count
- ADIL 1
- INBS 0
- Target Price
- ADIL $8.00
- INBS N/A
- AVG Volume (30 Days)
- ADIL 203.6K
- INBS 130.6K
- Earning Date
- ADIL 11-13-2024
- INBS 02-07-2025
- Dividend Yield
- ADIL N/A
- INBS N/A
- EPS Growth
- ADIL N/A
- INBS N/A
- EPS
- ADIL N/A
- INBS N/A
- Revenue
- ADIL N/A
- INBS $3,187,974.00
- Revenue This Year
- ADIL N/A
- INBS $280.88
- Revenue Next Year
- ADIL N/A
- INBS $126.26
- P/E Ratio
- ADIL N/A
- INBS N/A
- Revenue Growth
- ADIL N/A
- INBS 55.29
- 52 Week Low
- ADIL $0.77
- INBS $1.00
- 52 Week High
- ADIL $4.17
- INBS $11.70
- Technical
- Relative Strength Index (RSI)
- ADIL 55.23
- INBS 40.01
- Support Level
- ADIL $1.05
- INBS $1.36
- Resistance Level
- ADIL $1.27
- INBS $1.69
- Average True Range (ATR)
- ADIL 0.09
- INBS 0.10
- MACD
- ADIL -0.00
- INBS -0.03
- Stochastic Oscillator
- ADIL 46.88
- INBS 11.11
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).